NKTR Nektar Therapeutics

NASDAQ
$34.42

Nektar Therapeutics (NKTR) Earnings News

Earnings press releases, previews and reviews for Nektar Therapeutics (NKTR), newest first. Our most recent is review: Nektar's Per-Share Beat Owes Much to Dilution as Its Rezpeg Phase 3 Program Moves Into Execution, With Shares Down 48% Since the Last Report.